Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint - Chemdiv
TEVA Annual Report 2014 | PDF | Food And Drug Administration | Dividend
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire
Meet the Compound: Laquinimod – HD Insights
PDF) Effect of laquinimod on gray matter and white matter atrophy in relapsing-remitting multiple sclerosis: analysis of the BRAVO phase III trial
MS Therapy Laquinimod Fails to Meet Key Trial Goal of Slowing the Disease
Is Teva late reporting EU clinical trials?
PDF) Laquinimod safety profile: Pooled analyses from the ALLEGRO and BRAVO trials
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
PPMS Experimental Therapy Laquinimod Fails to Slow Brain Atrophy, Disease Progression
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Laquinimod treatment in the R6/2 mouse model | Scientific Reports
425
Patient enrollment in Phase III trial of laquinimod completed
Teva's MS pill misses the mark in PhIII trial - PharmaTimes
Teva returns laquinimod global rights to Active Biotech
Teva Showcases CNS Portfolio at 69th Annual Meeting of the American Academy of Neurology - Global Genes
Teva Terminates TV-45070 Development Agreement with Xenon
Teva May Have to Make Difficult Capital Allocation Decisions Under Pressure From Potential Generic Competition, Deleveraging Goals - Reorg
Teva drops laquinimod for most common form of MS after failed trial - PMLiVE
Teva Archives - Pharmaceutical Technology
425
MS Therapy Laquinimod Fails to Meet Key Trial Goal of Slowing the Disease
